IASO Bio
PrivateLast Round
Series C
Extension
Sep 1, 2025
Total Funding Raised
$303.4M
Company Overview
IASO Bio operates in Healthcare & Life Sciences and is based in Nanjing. Its latest recorded funding round was a Series C Extension round in September 2025.
IASO Bio is a biopharmaceutical company that develops innovative cell therapies and biologics for the treatment of hematological malignancies and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
IASO Bio Comparables
Compare IASO Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CARsgen Therapeutics | 87% | |
| Wuhan Bio-Raid Biotechnology | 85% | |
| Innovent Biologics | 84% |
For institutional investors. Book with your work email.
IASO Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Sep 1, 2025 | ||||
| Strategic | Jul 5, 2024 | ||||
| Series C Extension | Jan 17, 2023 | ||||
| Series C | Sep 16, 2021 | ||||
| Series B | Mar 24, 2020 | ||||
Series A | Oct 1, 2019 |
For institutional investors. Book with your work email.
IASO Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hongcheng Capital | Series C Extension |
| CDH Investments | Series C |
| CNCB Investment | Series C |
| CDH Baifu | Series C |
| Hillhouse Investment | Series B, Series A |
| Housen Care Brothers | Series C Extension |
| CCB International | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 10, 2026
Partnered with Instituto Butantan to expand access in Brazil.
- Oct 29, 2025
Partnered with GC Cell to enter the Korean market.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 11, 2026
IASO Bio plans to accelerate the global clinical development of IASO208, a China-originated in vivo CAR-T product, with larger clinical studies planned in China and the United States after early data show favorable tolerability and promising anti-tumor activity.
- partners_withNov 4, 2026
IASO Bio partners with Pills And Pokes Pte Ltd. in Singapore, jointly hosting a launch event for FUCASO on Nov 3rd '26 and supporting its stable supply and patient access.
- attends_eventNov 4, 2026
IASO Bio jointly hosts the FUCASO Singapore launch event with local partner Pills and Pokes in Singapore on Nov 3rd '26, marking FUCASO’s official commercial launch in Singapore.
- attends_eventSep 27, 2026
IASO Bio presents first-in-human Phase 1 clinical data for IASO206 at the 2026 International Myeloma Society (IMS) Annual Meeting on Sept. 26th '26.
- attends_eventSep 27, 2026
At the 2026 IMS Annual Meeting, IASO Bio presents data from the China real-world study of FUCASO showing a 95.9% objective response rate and a 77.2% complete or stringent complete response rate.
For institutional investors. Book with your work email.
IASO Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about IASO Bio's valuation, stock price, and market status.
Is IASO Bio a public or private company?
IASO Bio is a private company.
What is the current stock price of IASO Bio?
IASO Bio is a private company, so its shares have no public market price. Caplight tracks IASO Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is IASO Bio worth (valuation)?
Valuation information for IASO Bio is not publicly available.
Can I buy IASO Bio stock?
IASO Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was IASO Bio's last funding round?
IASO Bio's most recent funding round was Series C Extension on September 1, 2025.
Who are the main investors in IASO Bio?
Key investors in IASO Bio include CDH Investments, CNCB Investment, CDH Baifu, Hillhouse Investment, Housen Care Brothers.
Will IASO Bio IPO soon?
No public IPO plans have been announced for IASO Bio.
How can I track IASO Bio secondary market activity?
Caplight tracks bids, offers, and trades in IASO Bio's shares on secondary markets.